Subtopic Deep Dive
Mantle Cell Lymphoma Prognostication
Research Guide
What is Mantle Cell Lymphoma Prognostication?
Mantle Cell Lymphoma Prognostication involves risk stratification models like MIPI and biomarkers such as TP53 mutations and SOX11 expression to predict outcomes in this aggressive B-cell lymphoma subtype.
MIPI scoring integrates age, performance status, LDH, and leukemic phase for prognostic assessment (Jain and Wang, 2019). TP53 and CDKN2A deletions confer poor prognosis despite intensive therapies like high-dose cytarabine (Delfau-Larue et al., 2015). Genomic subtypes distinguish conventional MCL from leukemic non-nodal MCL with differing survival (Nadeu et al., 2020). Over 10 key papers from 2009-2022 detail these factors.
Why It Matters
Prognostication directs risk-adapted therapies, such as intensive hyper-CVAD for high-risk MCL patients with TP53 mutations, improving survival in heterogeneous cases (Jain and Wang, 2019; Delfau-Larue et al., 2015). MIPI guides autologous transplant decisions, with low-risk patients achieving median OS >10 years versus <2 years for high-risk (Jares et al., 2012). Genomic profiling identifies nnMCL subtypes responsive to BTK inhibitors, shifting management from chemotherapy to targeted agents (Nadeu et al., 2020; Singh et al., 2018).
Key Research Challenges
TP53 Mutation Heterogeneity
TP53 mutations predict resistance to intensive regimens but vary by subtype, complicating uniform risk models (Delfau-Larue et al., 2015). Detection methods differ in sensitivity across cohorts (Hill et al., 2020). Integration with MIPI remains inconsistent (Jain and Wang, 2019).
SOX11 Expression Variability
SOX11 levels stratify indolent versus aggressive MCL but lack standardized assays (Jares et al., 2012). Prognostic value weakens in relapsed settings (Nadeu et al., 2020). Correlation with genomic subtypes needs validation (Kridel et al., 2011).
MIPI Index Limitations
MIPI overlooks molecular markers like NOTCH1 mutations, underestimating risk in some patients (Jain and Wang, 2019). Poor performance in elderly cohorts limits applicability (Delfau-Larue et al., 2015). Updating for BTKi era remains unresolved (Hill et al., 2020).
Essential Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos et al. · 2022 · Leukemia · 3.3K citations
Role of Bruton’s tyrosine kinase in B cells and malignancies
Simar Pal Singh, Floris Dammeijer, Rudi W. Hendriks · 2018 · Molecular Cancer · 673 citations
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · 2015 · Annals of Oncology · 590 citations
Molecular pathogenesis of mantle cell lymphoma
Pedro Jares, Dolors Colomer, Elı́as Campo · 2012 · Journal of Clinical Investigation · 370 citations
Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways, and activation of cell survival mechanis...
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Robert Kridel, Barbara Meissner, Sanja Rogić et al. · 2011 · Blood · 332 citations
Abstract Mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma, is characterized by the hallmark translocation t(11;14)(q13;q32) and the resulting overexpression of cyclin D1 (C...
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Preetesh Jain, Michael Wang · 2019 · American Journal of Hematology · 259 citations
Abstract Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneit...
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
Ferran Nadeu, David Martin‐García, Guillem Clot et al. · 2020 · Blood · 206 citations
Abstract Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non-nodal MCL (nnMCL), that d...
Reading Guide
Foundational Papers
Start with Jares et al. (2012, 370 citations) for cyclin D1 pathogenesis and cell cycle basics; Kridel et al. (2011, 332 citations) for NOTCH1 mutations as early genomic insights.
Recent Advances
Jain and Wang (2019, 259 citations) for MIPI updates; Nadeu et al. (2020, 206 citations) for subtype epigenomics; Hill et al. (2020) meta-analysis of mutations.
Core Methods
MIPI scoring (age, LDH, PS, WBC); FISH/sequencing for TP53/CDKN2A; RNA-seq for SOX11/NOTCH1; Kaplan-Meier for survival validation (Delfau-Larue et al., 2015; Nadeu et al., 2020).
How PapersFlow Helps You Research Mantle Cell Lymphoma Prognostication
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Mantle Cell Lymphoma MIPI TP53' to map 20+ papers from Jain and Wang (2019), then findSimilarPapers uncovers Delfau-Larue et al. (2015) on TP53 deletions, revealing 259-cited hubs.
Analyze & Verify
Analysis Agent applies readPaperContent to extract TP53 deletion rates from Delfau-Larue et al. (2015), verifies MIPI scores via runPythonAnalysis on survival data with Kaplan-Meier plots, and assigns GRADE B evidence for prognostic claims using verifyResponse (CoVe).
Synthesize & Write
Synthesis Agent detects gaps in TP53-MIPI integration across papers, flags contradictions between subtypes (Nadeu et al., 2020), while Writing Agent uses latexEditText, latexSyncCitations for 15 references, and latexCompile to generate a risk model table.
Use Cases
"Run survival analysis on TP53 mutated MCL patients from high-citation papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas Kaplan-Meier on extracted OS data from Delfau-Larue 2015) → matplotlib plot of hazard ratios.
"Draft LaTeX review on MCL prognostication with MIPI and genomic biomarkers"
Synthesis Agent → gap detection → Writing Agent → latexEditText (add sections) → latexSyncCitations (15 papers) → latexCompile → PDF with formatted MIPI table.
"Find code for MCL genomic subtype analysis"
Research Agent → paperExtractUrls (Nadeu 2020) → paperFindGithubRepo → githubRepoInspect → exportCsv of mutation frequencies for local R analysis.
Automated Workflows
Deep Research workflow scans 50+ MCL papers via citationGraph, structures MIPI/TP53 report with GRADE grading in 7 steps. DeepScan verifies TP53 prognostic claims across Delfau-Larue (2015) and Hill (2020) using CoVe checkpoints. Theorizer generates hypotheses on nnMCL BTKi response from Nadeu (2020) genomic data.
Frequently Asked Questions
What defines Mantle Cell Lymphoma Prognostication?
It uses MIPI scores, TP53 mutations, and SOX11 expression for risk stratification in MCL (Jain and Wang, 2019).
What are main prognostication methods?
MIPI combines clinical factors; TP53/CDKN2A deletions predict poor outcomes; genomic subtyping differentiates cMCL from nnMCL (Delfau-Larue et al., 2015; Nadeu et al., 2020).
What are key papers?
Jain and Wang (2019, 259 citations) updates MIPI; Delfau-Larue et al. (2015) shows TP53 persistence; Jares et al. (2012, 370 citations) details pathogenesis (Jares et al., 2012).
What open problems exist?
Integrating molecular markers into MIPI for BTKi era; standardizing SOX11 assays; validating in elderly cohorts (Hill et al., 2020; Jain and Wang, 2019).
Research Lymphoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mantle Cell Lymphoma Prognostication with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lymphoma Diagnosis and Treatment Research Guide